Insider transactions

Novartis Bioventures Ltd

CIK 1297709 · last filed 2020-06-22

Novartis Bioventures Ltd is a corporate insider who has filed 44 SEC Form 4 insider transactions across 11 companies since 2011. The most recent filing shows the insider sold $16.5M of GRTX on Jun 22, 2020. Across all open-market trades the lifetime net is −$22.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $25.1M across reported positions. The firm reports its address in Ch-4002 Basel, V8. 85 SEC filings were submitted jointly with NOVARTIS AG.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$25.08M
Companies
11
Total Filings
44
Lifetime Open-Market Net
-$21.96M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

GRTX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O NOVARTIS INTERNATIONAL AG
WSJ-200.220
CH-4002 BASEL, V8 0000000000
Phone
41-61-324-6210
State of Incorporation
Bermuda
Related Filers
NOVARTIS AG — 85 joint filings, latest 2020-07-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Galera Therapeutics, Inc. (GRTX) Delisted 10%+ Owner 35,061 $17.60 $617.1K -$11.18M 4 2020-06-22
BCYC 10%+ Owner 1,769,641 $3.62 $6.41M $4.72M 1 2019-05-30
Whitehawk Therapeutics, Inc. (ARPO) Delisted 10%+ Owner 279,234 $33.00 $9.21M -$2.89M 6 2019-04-29
Rein Therapeutics, Inc. (ALRN) Delisted 10%+ Owner 105,000 $2.11 $221.6K -$1.69M 9 2019-04-02
ALT 10%+ Owner 8,345,145 $2.23 $18.57M $0 8 2018-09-14
Spyre Therapeutics, Inc. (AGLE) Delisted 10%+ Owner 87,013 $12.01 $1.05M -$2.74M 3 2018-05-14
Ra Pharmaceuticals, Inc. (RARX) Delisted 10%+ Owner 2,254,677 — — -$12.06M 7 2017-06-20
Eledon Pharmaceuticals, Inc. (TKAI) Delisted 10%+ Owner 499,273 — — -$133.7K 2 2015-07-17
AKBA 10%+ Owner 182,590 $0.60 $109.6K $3.10M 1 2014-03-27
Eiger BioPharmaceuticals, Inc. (CLDN) Delisted 10%+ Owner 103,448 — — $1.30M 1 2014-02-06
Adhera Therapeutics, Inc. (MRNAD) Delisted 10%+ Owner 2,560,565 — — -$383.4K 1 2011-01-27

Recent Filings

44 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-06-22 Galera Therapeutics, Inc. (GRTX) Delisted Sell (S) −2,004,424 -$16.54M EDGAR
2020-06-17 Galera Therapeutics, Inc. (GRTX) Delisted Sell (S) −38,772 -$357.2K EDGAR
2020-06-04 Galera Therapeutics, Inc. (GRTX) Delisted Sell (S) −29,930 -$289.7K EDGAR
2019-11-12 Galera Therapeutics, Inc. (GRTX) Delisted Mixed +7,086,134 $6.00M EDGAR
2019-05-30 BCYC Mixed +3,539,282 $4.72M EDGAR
2019-04-29 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −1,403,600 -$1.45M EDGAR
2019-04-24 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −102,114 -$104.3K EDGAR
2019-04-15 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −234,280 -$245.4K EDGAR
2019-04-10 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −401,492 -$428.5K EDGAR
2019-04-02 Rein Therapeutics, Inc. (ALRN) Delisted Sell (S) −254,300 -$472.5K EDGAR
Showing 1–10 of 44
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.